PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18322300-2	2008	This study was performed to explore whether the well-known clinical, hormonal and metabolic efficacy of metformin or rosiglitazone treatment is reflected in the modulation of adipocyte GLUT4 mRNA expression in patients with PCOS.	Rosiglitazone	117-130	solute carrier family 2 member 4	Homo sapiens	185-190	
18322300-12	2008	CONCLUSIONS: A 6-month therapy with insulin sensitizers resulted in marked improvement in adipose tissue GLUT4 mRNA expression in PCOS patients, rosiglitazone being more effective when compared with metformin.	Rosiglitazone	145-158	solute carrier family 2 member 4	Homo sapiens	105-110	
29676131-9	2018	The protein expression levels of IRS2, PI3KR1, p-AKT (Ser473), p-AMPK (Thr172), GLUT4/1/2 were significantly up-regulated by different concentrations of jatrorrhizine and rosiglitazone (P<0.01).	Rosiglitazone	171-184	solute carrier family 2 member 4	Homo sapiens	80-89	
25596527-8	2015	ZFP407 was required for the PPARgamma agonist rosiglitazone to increase Glut4 expression, but was not sufficient to increase expression of a PPARgamma target gene reporter construct.	Rosiglitazone	46-59	solute carrier family 2 member 4	Homo sapiens	72-77	
20026082-0	2010	Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling.	Rosiglitazone	0-13	solute carrier family 2 member 4	Homo sapiens	37-42	
20026082-4	2010	The aim of this study was to evaluate the effect of the thiazolidinedione rosiglitazone (BRL 49653) on GLUT4 in adipocytes.	Rosiglitazone	74-87	solute carrier family 2 member 4	Homo sapiens	103-108	
20026082-5	2010	When applied during differentiation, rosiglitazone dose dependently augmented GLUT4 expression along with the formation of lipid droplets.	Rosiglitazone	37-50	solute carrier family 2 member 4	Homo sapiens	78-83	
20026082-7	2010	Treatment of fully differentiated adipocytes with rosiglitazone also led to increases in GLUT4 at the plasma membrane.	Rosiglitazone	50-63	solute carrier family 2 member 4	Homo sapiens	89-94	
20026082-9	2010	The augmentation in cell surface GLUT4 levels was maintained in adipocytes that were rendered insulin-resistant in vitro by a 24h insulin treatment and moreover in these cells rosiglitazone also fully restored insulin-induced GLUT4 translocation.	Rosiglitazone	176-189	solute carrier family 2 member 4	Homo sapiens	33-38	
20026082-9	2010	The augmentation in cell surface GLUT4 levels was maintained in adipocytes that were rendered insulin-resistant in vitro by a 24h insulin treatment and moreover in these cells rosiglitazone also fully restored insulin-induced GLUT4 translocation.	Rosiglitazone	176-189	solute carrier family 2 member 4	Homo sapiens	226-231	
20026082-10	2010	We conclude that in adipocytes, rosiglitazone increases cell surface GLUT4 levels by increasing its endosomal recycling and restores insulin-induced GLUT4 translocation in insulin resistance.	Rosiglitazone	32-45	solute carrier family 2 member 4	Homo sapiens	69-74	
20026082-10	2010	We conclude that in adipocytes, rosiglitazone increases cell surface GLUT4 levels by increasing its endosomal recycling and restores insulin-induced GLUT4 translocation in insulin resistance.	Rosiglitazone	32-45	solute carrier family 2 member 4	Homo sapiens	149-154	
20026082-11	2010	These results implicate novel modes of action on GLUT4 that are all likely to contribute to the insulin-sensitizing effect of rosiglitazone in type 2 diabetes.	Rosiglitazone	126-139	solute carrier family 2 member 4	Homo sapiens	49-54	
15864539-0	2005	Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1.	Rosiglitazone	84-97	solute carrier family 2 member 4	Homo sapiens	146-151	
15864539-8	2005	Exposure to insulin, rosiglitazone or metformin increased mRNA expression of PGC1 and GLUT4, while AICAR or 25 mmol/l glucose treatment increased GLUT1 mRNA expression.	Rosiglitazone	21-34	solute carrier family 2 member 4	Homo sapiens	86-91	
11579205-5	2001	Rosiglitazone treatment for 48 h significantly increased basal and insulin-stimulated glucose uptake and markedly increased the cellular expression of GLUT1 but not GLUT4.	Rosiglitazone	0-13	solute carrier family 2 member 4	Homo sapiens	165-170	
21167254-1	2011	Rosiglitazone (Rosi) improves insulin sensitivity and increases the translocation of glucose transporter 4 (GLUT4) to the plasma membrane (PM).	Rosiglitazone	0-13	solute carrier family 2 member 4	Homo sapiens	85-106	
21167254-1	2011	Rosiglitazone (Rosi) improves insulin sensitivity and increases the translocation of glucose transporter 4 (GLUT4) to the plasma membrane (PM).	Rosiglitazone	0-13	solute carrier family 2 member 4	Homo sapiens	108-113	
21167254-1	2011	Rosiglitazone (Rosi) improves insulin sensitivity and increases the translocation of glucose transporter 4 (GLUT4) to the plasma membrane (PM).	Rosiglitazone	0-4	solute carrier family 2 member 4	Homo sapiens	85-106	
21167254-1	2011	Rosiglitazone (Rosi) improves insulin sensitivity and increases the translocation of glucose transporter 4 (GLUT4) to the plasma membrane (PM).	Rosiglitazone	0-4	solute carrier family 2 member 4	Homo sapiens	108-113